Gene therapy’s growing clinical footprint drew another spotlight as the Breakthrough Prize Foundation handed the Life Sciences prize to two pioneering teams. One effort, led by physician-scientists Jean Bennett, Albert Maguire, and Katherine High at the University of Pennsylvania, traces the path from early retinal gene targeting to a therapy already in routine use in multiple countries. Separately, Swee Lay Thein (now at the National Heart, Lung, and Blood Institute) and Harvard physician scientist Stuart Orkin were recognized for work connecting the gene responsible for persistent fetal hemoglobin to beta thalassemia and sickle cell disease, bringing discoveries “from bench to bedside.” The announcement underscored how sustained translational pipelines can turn single-gene insights into usable therapies. The prize coverage also provides a reminder of the durability challenges that early gene delivery work faced, with the teams having iterated on vector design and delivery to improve outcomes over time. Overall, the Breakthrough awards point to continuing momentum in gene-based medicine, including clinical validation spanning ophthalmology and hematology.